Sumit Verna, Iovance iCTC site head, at the ribbon cutting ceremony. He is joined by Fred Vogt, Iovance CEO, Governor Tom Wolf, and Mayor Jim Kenney.

Iovance Biotherapeutics Celebrates Grand Opening of Iovance Cell Therapy Center (iCTC)

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), is celebrating the official opening of the Iovance Cell Therapy Center (iCTC). The iCTC, located at the Philadelphia Navy Yard, is the first centralized, scalable, state-of-the-art manufacturing facility dedicated to producing TIL cell therapies for patients with solid tumor cancers. The current capacity is expected to meet potential demand for thousands of patients per year with multiple types of cancers, including clinical trial patients and future commercial patients.

Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, “Since Iovance was founded, we have been dedicated to advancing novel cell therapies for patients with solid tumor cancers. As the hub of cell and gene therapy and the home of leading hospitals and academic centers, Philadelphia became the city of choice for our internal manufacturing. A little over two years after breaking ground, iCTC is now one of the largest cell therapy manufacturing facilities in the world and may ultimately house hundreds of employees. We now have the capacity to supply broad access to TIL therapies for patients. I believe that the important ecosystem within Cellicon Valley will continue to contribute to our advancements to pioneer a new class of treatment for cancer.”

A ribbon cutting event celebrates the opening with special guests including Pennsylvania Governor Tom Wolf, Philadelphia Mayor Jim Kenney, and other government officials and collaborators within Cellicon Valley. Patients, caregivers, and patient advocacy organizations, including Melanoma Research Foundation (MRF), Melanoma Research Alliance (MRA) and the Society for Gynecological Oncology’s Foundation for Women’s Cancer cut the ribbon on behalf of everyone who is currently fighting cancer, and in memory of those who lost their battles with cancer.

Sumit Verna, Iovance iCTC site head, at the ribbon cutting ceremony. He is joined by Fred Vogt, Iovance CEO, Governor Tom Wolf, and Mayor Jim Kenney.

“The iCTC is a symbol of significant innovation and opportunity for the commonwealth as hundreds of new, high-paying jobs will ultimately be created at this facility,” said Governor Tom Wolf. “Iovance has already made a positive impact on the region and worked with a great sense of urgency to complete construction and begin initial manufacturing for patients with cancer.”

“The iCTC represents a new model in cell therapy manufacturing and bolsters Philadelphia’s reputation as a leading location for technology, innovation, and life sciences,” said City of Philadelphia Mayor Jim Kenney. “Iovance is a great example of what companies from around the country and the world may accomplish in establishing Philadelphia as the place to attract talent and grow their business.”

Located at 300 Rouse Boulevard and with approximately 136,000 square feet of space, the iCTC is among the largest cell therapy manufacturing facilities today. The iCTC is currently supplying Iovance clinical studies, and commercial manufacturing is expected to begin after initial product approval. The iCTC was developed and built by Gattuso Development Partners, LLC and the design and construction management firm CRB. Financial incentives were provided by the Commonwealth of Pennsylvania, the City of Philadelphia, and PIDC, including the site’s designation as a Keystone Opportunity Improvement Zone, which allows incentives for business development.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer. TIL cells are extracted from a patient’s own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company’s TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers. For more information, please visit www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). All such written or oral statements made in this press release, other than statements of historical fact, are forward-looking statements and are intended to be covered by the safe harbor for forward-looking statements provided by the PSLRA. Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the effects of the COVID-19 pandemic; risks related to the timing of and our ability to successfully develop, submit, obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, our product candidates, and our ability to successfully commercialize any product candidates for which we obtain FDA approval; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the new version of the protocol which further defines the patient population to include more advanced patients in our cervical cancer trial may have an adverse effect on the results reported to date; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA may differ from the interpretation of such results or communications by the FDA; the acceptance by the market of our product candidates and their potential reimbursement by payors, if approved; our ability or inability to manufacture our therapies using third party manufacturers or our own facility may adversely affect our potential commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; and other factors, including general economic conditions and regulatory developments, not within our control.

CONTACTS

Iovance Biotherapeutics, Inc:
Sara Pellegrino, IRC
Vice President, Investor Relations & Public Relations
650-260-7120 ext. 264
Sara.Pellegrino@iovance.com

Solebury Trout:
Zara Lockshin
646.378.2960
zlockshin@soleburytrout.com

Tour of the Philly Shipyard, Inc. facilities in front of the iconic goliath crane [photo by Ben Bowens Photography]

Philly Shipyard Hires 13 PIDC Workforce Development Program Graduates

PIDC and University City District’s West Philadelphia Skills Initiative is thrilled to announce that we graduated and placed 14 program participants from our second Navy Yard Workforce Development Initiatives training program today!  These participants completed the three-week Shipyard Laborer Program in partnership with Philly Shipyard Inc. and 13 were extended a job offer for full-time permanent employment in the government and commercial shipbuilding industry starting at $14.00/hour.

Shipyard Laborer Program Graduates

We partnered with Navy Yard company Philly Shipyard, Inc., a leading U.S. shipbuilder presently pursuing a mix of commercial and government work, ranging from shipbuilding to repair and maintenance, who had a large hiring need due to National Security Multi-Mission Vessels (NSMV) contracts. Over 220 applications were submitted, more than 100 applicants were invited to interview, and just 17 people were accepted into the program. With the placement of 14 participants, the job placement rate for this program is 93%!

Classroom session at Penn State at the Navy Yard [photo by Ben Bowens Photography]

The Shipyard Laborer Program is designed to connect participants to the professional and technical training, tools, and supports needed to build a meaningful career at Philly Shipyard. This three-week program included 37+ hours of in-person training and coaching using the classroom space at Penn State at the Navy Yard, 10 hours of safety training to earn an OSHA-10 certification, 4 hours of basic life support and CPR training, and one worksite visit touring the Philly Shipyard campus and meeting with the staff. 

Tour of the Philly Shipyard, Inc. facilities in front of the iconic goliath crane [photo by Ben Bowens Photography]

This program the second of four collaborative professional development training programs managed by West Philadelphia Skills Initiative (WPSI) and PIDC’s Navy Yard Workforce Development Initiatives (NYWDI) to train Philadelphia residents for permanent, full-time, quality-wage careers at the Navy Yard.We are looking forward to many more successful programs connecting Philadelphians to life changing careers. 

Tour of the Philly Shipyard, Inc. facilities [photo by Ben Bowens Photography]

Chapel Block Images_11

Ensemble/Mosaic Announces Plans for Chapel Block, the First Residential Development at the Navy Yard Since the 1996 Base Closure

Ensemble/Mosaic today announced plans to develop the first residential complex to be built at the Philadelphia Navy Yard as part of its agreement with PIDC. The company plans to break ground on the project in 2022 and open the complex in 2024.

“Ensemble/Mosaic is on the cusp of reaching a longstanding, identity-shifting objective – to evolve the Navy Yard into a fully functioning Philadelphia neighborhood,” said Brian Cohen, Senior Vice President, Ensemble. “We are incredibly excited at the prospect of creating a vibrant and diverse residential community so people may further enjoy this unique location and all it has to offer.”

Located at 1200 Normandy Place, the complex, called Chapel Block, will include a seven-story building and two connected six-story buildings. In total, it will offer 611 luxury and mixed-income apartments offering 40 different unit sizes and bedroom configurations, and options for furnished and unfurnished units.

It will also include 75,000 square feet of indoor and outdoor resident amenity space and 26,000 square feet of space for restaurants and retail. All three buildings are designed to meet a minimum of LEED® Silver certification from the United States Green Building Council, providing for a sustainable and healthy living experience.

Design Informed by the Pandemic

“The pandemic was foremost in our thinking as we developed this project, keeping in mind the new realities of how people work, value outdoor access and are concerned about indoor ventilation,” said Leslie Smallwood-Lewis, Founder and Owner, Mosaic. “Home should be every resident’s ‘safe place,’ and our goal has been to incorporate as much as we can of what we have learned in the last 18 months so that residents will be comfortable and secure in their homes here.”

Some of the steps the team has taken include:

  • A significant number of units will include areas to accommodate working from home, with separate offices or built-in work areas.
  • Proximity to three parks: five-acre Central Green with a running track, outdoor table tennis, bocce, cross-fit station, amphitheater, and picnic areas; three-acre League Island Park, a natural and serene park for lounging and working; and eight-acre Marine Parade Grounds, a historic public space that provides fields for sport leagues, food trucks, and large outdoor events.
  • LEED certification with an emphasis on a healthy living environment with high indoor air quality.
  • Expanded building amenity offerings and areas to work from outside of apartments.

Chapel Block: A Community of Three Buildings, Dozens of Options

Chapel Block takes its name from the historic Chapel constructed by the Navy in 1942 on the southeast corner of the block to be developed.  The chapel is now occupied by the Chapel of the Four Chaplains and Memorial Foundation, dedicated to promoting interfaith cooperation and selfless service of individuals and organizations. It honors the moving story of four chaplains who died while saving many lives when The Dorchester, a U.S. Army transport ship (USAT), was sunk in the waters of Newfoundland during World War Two.

“One of the most interesting aspects of developing in the Navy Yard is that we are surrounded by critical U.S. history on a daily basis,” said Cohen. “This is a place filled with stories of bravery and heroism. It is an inspiring location and one we love to share with residents, employees and visitors.”

The seven-story building will be developed on the north end of the Chapel Block site in partnership with Korman Communities under their exciting residential real estate brand, “AVE.”

AVE Navy Yard will feature 265 luxury units, a portion of which will be reserved as flexible-stay, fully furnished apartments offered on a monthly basis for individuals who need a temporary living option. On-demand amenities will include a resort pool, media theatre, fire pit lounge, grilling stations, executive meeting spaces, a golf simulator, music studio, and pet spa.

“We are thrilled to partner with Ensemble/Mosaic on this exciting project,” said Bradley J. Korman, co-CEO of Korman Communities. “Philadelphia is our home, and we are honored to be a part of this incredible opportunity to develop what will become one of the most desirable locations to live, work, and play in the region.”

On the south end of Chapel Block, the two six-story buildings will form a mixed-income project containing 346 market rate and affordable units.  It is designed as two separate structures and will be connected on the ground floor by shared amenities including a fitness center, business center, lounge areas, a game area, a party room with gourmet kitchen, pet spa, and bike storage.  The connected buildings are situated around a private courtyard with lounge seating fire pits and grill stations.

“Chapel Block will change the Navy Yard in many exciting ways. This addition of new  mixed-income residential for the first time since the naval base was closed over two decades ago will serve not only the employees and visitors of the Navy Yard, but everyone who lives on site, too,” said Kate McNamara, PIDC’s Senior Vice President, Navy Yard.

The complex is designed by a partnership of two architectural firms, Philadelphia-based DIGSAU, the design architect, which has designed several buildings in the Navy Yard, and Moody Nolan, the architect of record, headquartered in Columbus, OH. Moody Nolan is the 2021 AIA Firm of the Year and the largest minority owned architecture firm in the country.

“Two exceptional architectural firms have banded together to bring us a design that will change the Navy Yard for decades by creating residential opportunities for people from all walks of life,” said Smallwood-Lewis. “We are excited that they have brought opportunity to many smaller and specialty firms, as more than 50% of the design work is being done by 15 different MBE/WBE-certified firms in Philadelphia and around the country.”

Through its development agreement with PIDC, Ensemble/Mosaic will redevelop 109 acres of land through renovation and ground-up construction, including Chapel Block. The developer will invest $2.6B – with all funds fully committed to ESG (environmental, social and governance) – over the next two decades, of which $1B has been commitment to DEI (diversity, equity and inclusion.)

After the naval base closure in 1996, the City of Philadelphia, PIDC, Philadelphia’s public-private economic development corporation and master developer of the Navy Yard, and its partners envisioned the redevelopment of the space into a thriving mixed-use campus, restoring it as an economic engine for the city. Over the last two decades, the Navy Yard has attracted 170 businesses employing more than 15,000 personnel.

Ensemble/Mosaic is working with PIDC and the U.S. Navy to complete the technical steps necessary to lift the residential deed restriction on this parcel.

“We thank our partners at the Navy for working with us to on this new development, which will further the Navy Yard’s position as one of Philadelphia’s most unique business campuses and evolving neighborhoods,” added McNamara.